Psoriatic arthritis

      ❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of m

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      ❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB
      MONITOR PsA 200+ pts secondary care "real-life" cohort
      65 treated w/ combi csDMARDs
      48weeks outcome and 96 weeks
      49% bi

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD ‼️reasons for discontinuation was AEs in 60% cases not inefficacy Caveat: analysis not adjusted for https://t.co/L8EczgZTpP
      📊 POS0574 @rheumnow #EULAR2025Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA

      Jiha Lee JihaRheum

      4 months 2 weeks ago

      📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3

      MONITOR-PsA (n=218):
      •36.5% had >1 csDMARD
      •Of those, 49.2% tried combination (combo) csDMARDs
      •63.6% of combo

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      MONITOR-PsA (n=218): •36.5% had >1 csDMARD •Of those, 49.2% tried combination (combo) csDMARDs •63.6% of combo csDMARD users in MDA at 48wks •61.1% stopped due to side effects—not inefficacy Real-world support for csDMARD combos where biologics delayed. Abstract#OP0093 https://t.co/3Anme39VXk
      Early PsA? Treat fast, treat hard.

      The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 res

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16
      Combination therapies in PsA not so far away:
      -Case series of 22 patients from large PsA cohort.
      -Combination therapy in

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Combination therapies in PsA not so far away: -Case series of 22 patients from large PsA cohort. -Combination therapy in PsA used when difficult to treat skin and msk involvement. -Deucravacitinib was the agent mostly used in combination with bDMARDs. -No major serious adverse https://t.co/YUyvuaJcsE
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR
      IL17i + JAKi 10.5 PY = 1 mild infectio

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ
      Can IL-17F signalling be modulated by treatment with TNFi?
      In PsA pts non responders to previous TNFi, there was increas

      Adela Castro AdelaCastro222

      4 months 2 weeks ago
      Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz
      In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not a

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA. @RheumNow #EULAR2025 #OP0028
      Early intensive therapy in PsA.
      STAMP RCT in early PsA:
      •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
      •MDA at

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX
      Should we start strong in PsA?

      In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Should we start strong in PsA? In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w. Abstract#OP0089 @RheumNow #EULAR2025
      older woman with clasped hands
      Late-Onset Disease: Different Age, Different Rules?
      4 months 2 weeks ago
      We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related biology, comorbidity, and the biases that influence medical decision-making? Several abstracts presented at EULAR 2025 challenge us to reconsider how we diagnose and treat rheumatic disease in older adults.

      Catch up on Conference Podcasts

      ×